Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and [...]
Cullinan Oncology Completes $131.2 Million Series C Financing
Cullinan Oncology Completes $131.2 Million Series C Financing [...]
Jon Wigginton MD Receives SITC Visionary Legacy Award
Jon Wigginton MD Receives SITC Visionary Legacy Award [...]
Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer
Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer [...]
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy [...]
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML
Cullinan Oncology, German Cancer Research Center (DKFZ) and the [...]
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine [...]
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, [...]
Cullinan Oncology Completes $98.5 Million Series B Financing
Cullinan Oncology Completes $98.5 Million Series B Financing [...]
Cullinan Oncology Announces First Patients Dosed with Drug Candidates from Cullinan Apollo and Cullinan Pearl
Cullinan Oncology Announces First Patients Dosed with Drug Candidates [...]
Cullinan Co-Founder Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy
Patrick Baeuerle Recognized for Contributions to Cancer Immunotherapy [...]
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop [...]
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The [...]
Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company
CAMBRIDGE, Mass., October 3, 2017 - - Cullinan Oncology, LLC announced today a $150 million Series A financing co-led by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures.